Gadoversetamide | CAS# 131069-91-5 | nonionic, linear chelate

MedKoo Cat#: 414599 | Name: Gadoversetamide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gadoversetamide is a nonionic, linear chelate used for magnetic resonance imaging of brain and spine.

Chemical Structure

Gadoversetamide

CAS#131069-91-5

Theoretical Analysis

MedKoo Cat#: 414599

Name: Gadoversetamide

CAS#: 131069-91-5

Chemical Formula: C20H37GdN5O10

Exact Mass: 665.1781

Molecular Weight: 664.79

Elemental Analysis: C, 36.13; H, 5.61; Gd, 23.65; N, 10.53; O, 24.07

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Gadoversetamide; MP-1177; MP1177; MP 1177; HSDB7550; HSDB-7550; HSDB 7550

IUPAC/Chemical Name

(8,11-Bis(carboxymethyl)-14-(2-((2-methoxyethyl)amino)-2-oxoethyl)-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)), gadolinium

InChi Key

OKVNYJNFJCLPRF-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);

SMILES Code

COCCNC1=O[Gd+3]234567N(CCN5(C1)CC([O-]6)=O)(CC([O-]7)=O)CCN2(CC(NCCOC)=O4)CC([O-]3)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 664.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Cheng KT. Gadoversetamide: Gd-DTPA-BMEA. 2007 Nov 7 [updated 2007 Dec 10]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641436. 2: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Gadoversetamide. 2019 Feb 28. PMID: 30000471. 3: Huber S, Muthupillai R, Cheong B, Wible JH Jr, Shah D, Woodard P, Grothues F, Mahrholdt H, Rochitte CE, Masoli O, Kim RJ, Schwaiger CM, Fuisz A, Kramer C, van Rossum AC, Biederman R, Lombardi M, Martin E, Kevorkian R, Flamm SD. Safety of gadoversetamide in patients with acute and chronic myocardial infarction. J Magn Reson Imaging. 2008 Dec;28(6):1368-78. doi: 10.1002/jmri.21502. PMID: 19025944. 4: Wible JH Jr, Tata PN, Napoli AM, Lowe LH, Kearns GL. Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients. Magn Reson Imaging. 2009 May;27(4):512-8. doi: 10.1016/j.mri.2008.08.002. Epub 2008 Sep 23. PMID: 18814985. 5: Lowe LH, Kearns GL, Wible JH Jr. The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. Curr Med Res Opin. 2006 Dec;22(12):2515-24. doi: 10.1185/030079906X159452. PMID: 17166334. 6: Wible JH Jr, Galen KP, Wojdyla JK. Cardiovascular effects caused by rapid administration of gadoversetamide injection in anesthetized dogs. Invest Radiol. 2001 May;36(5):292-8. doi: 10.1097/00004424-200105000-00007. PMID: 11394361. 7: Wible JH Jr, Troup CM, Hynes MR, Galen KP, MacDonald JR, Barco SJ, Wojdyla JK, Periasamy MP, Adams MD. Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging. Invest Radiol. 2001 Jul;36(7):401-12. doi: 10.1097/00004424-200107000-00006. PMID: 11496095. 8: Wible JH Jr, Hynes MR. Measurement of serum calcium concentration after administration of gadoversetamide in dogs. Radiology. 2004 Oct;233(1):158-64. doi: 10.1148/radiol.2331031689. PMID: 15454620. 9: Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, Parker M, Napoli A, Judd RM; Gadoversetamide Myocardial Infarction Imaging Investigators. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation. 2008 Feb 5;117(5):629-37. doi: 10.1161/CIRCULATIONAHA.107.723262. Epub 2008 Jan 22. PMID: 18212288. 10: Gandhi MJ, Narra VR, Brown JJ, Guo A, Grosu DS, Parvin CA, Scott MG. Clinical and economic impact of falsely decreased calcium values caused by gadoversetamide interference. AJR Am J Roentgenol. 2008 Mar;190(3):W213-7. doi: 10.2214/AJR.07.2923. PMID: 18287415.